Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase 3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 440Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 246Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 118Carcinoma, Renal Cell 103Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Giant Cell Tumor of Bone × Clear all
NCT04255576 2022-10-14

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Shanghai JMT-Bio Inc.

Phase 1/2 Unknown
139 enrolled

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡